This article was originally published on TipRanks.com Jazz Pharmaceuticals plc (NASDAQ: JAZZ), a global biopharmaceutical company, has revealed that Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution has …
Jazz Pharmaceuticals on Feb. 3 announced the acquisition of GW Pharmaceuticals for a total consideration of $7.
Jazz Pharmaceuticals (JAZZ) and partner PharmaMar have announced a surprise early approval from the US FDA for its Zepzelca treatment for adults with …
Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) stock is on a 9% rise after receiving abbreviated new drug application (ANDA) approval as well …
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced that the first patient has been enrolled in a Phase 3 clinical trial comparing the efficacy and safety …
Analyst Irina Koffler from Mizuho Securities reiterated her Buy rating on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) with a raised price target of $195, marking …
Celator Pharmaceuticals Inc (NASDAQ:CPXX) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced that they have entered into a definitive agreement for Jazz Pharmaceuticals to acquire Celator …
Leerink Swann’s healthcare analysts came out today with favorable reports on pharmaceutical giants Gilead Sciences, Inc. (NASDAQ:GILD) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ).
Cantor analyst Irina Rivkind was out today pounding the table on Jazz Pharmaceuticals (NASDAQ:JAZZ) Monday, reiterating a Hold rating and a price target of $195. …
In a research report issued today, Cantor analyst Irina Rivkind assigned a Hold rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) and raised her price target to …
